OTCMKTS:OXBDF Oxford Biomedica (OXBDF) Stock Price, News & Analysis → How a $0.25 cent option contract makes my top traders feel (From DTI) (Ad) Free OXBDF Stock Alerts $2.91 +0.09 (+3.19%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$2.85▼$2.9150-Day Range$2.09▼$2.9152-Week Range$2.09▼$6.02Volume1,100 shsAverage Volume212 shsMarket Capitalization$280.12 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get Oxford Biomedica alerts: Email Address Ad DTIMy top 100 stocks…We recently ran an internal audit of every trade recommendation I’ve published across all my services… And let me tell ya, we found some incredible insights… For starters, we found about 100 stocks I trade really, really well.Get some cool freebies right here. About Oxford Biomedica Stock (OTCMKTS:OXBDF)Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.Read More OXBDF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OXBDF Stock News HeadlinesApril 20, 2024 | barrons.comOxford BioMedica PLCMarch 30, 2024 | finance.yahoo.comOxford Biomedica Insiders Placed Bullish Bets Worth UK£415.3kApril 27, 2024 | Investing Daily (Ad)They say it’s ‘unstoppable’ – How I made 43,509% Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.January 23, 2024 | investing.comOxford BioMedica PLC (OXB)January 23, 2024 | finance.yahoo.comOxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturingNovember 5, 2023 | morningstar.comOxford BioMedica PLC OXOASeptember 25, 2023 | finance.yahoo.comAnalysts Just Slashed Their Oxford Biomedica plc (LON:OXB) EPS NumbersSeptember 21, 2023 | msn.comOxford BioMedica shares boom as manufacturer expands complex cancer therapiesApril 27, 2024 | Investing Daily (Ad)They say it’s ‘unstoppable’ – How I made 43,509% Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.September 20, 2023 | lse.co.ukOxford BioMedica shares up, in talks to buy ABL Europe but loss widensSeptember 20, 2023 | msn.comOxford Biomedica stock soars on rosy forecast, talks to buy ABL EuropeSeptember 20, 2023 | marketwatch.comOxford BioMedica Shares Rise on Transformational Deal Talks, Revenue Growth ExpectationSeptember 20, 2023 | finance.yahoo.comOxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformationSeptember 20, 2023 | finance.yahoo.comKyverna Therapeutics and Oxford Biomedica Sign License and Supply Agreement for LentiVector® PlatformSeptember 7, 2023 | finance.yahoo.comOxford Biomedica to host webinar showcasing the TetraVecta™ systemJuly 10, 2023 | finance.yahoo.comOxford Biomedica (LON:OXB) shareholders have endured a 50% loss from investing in the stock five years agoJune 23, 2023 | marketwatch.comOxford BioMedica's Executive Pay Report Gets Low Shareholder Support at Annual MeetingFebruary 20, 2023 | finance.yahoo.comDr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023January 30, 2023 | finance.yahoo.comThe past year for Oxford Biomedica (LON:OXB) investors has not been profitableNovember 14, 2022 | finance.yahoo.comOxford Biomedica to complete sale and leaseback of Windrush Court facility for £60 millionSeptember 15, 2022 | lse.co.ukOxford BioMedica swings to interim loss as costs climb, revenue fallsAugust 19, 2022 | finance.yahoo.comOxford Biomedica (LON:OXB) shareholders have endured a 66% loss from investing in the stock a year agoJuly 26, 2022 | lse.co.ukOxford BioMedica begins new project and signs license agreementJuly 26, 2022 | finance.yahoo.comOxford Biomedica Signs Licence & Supply Agreement with New Partner for LentiVector® Platform for CAR-T TherapyJuly 16, 2022 | finance.yahoo.comOxford Biomedica plc's (LON:OXB) Intrinsic Value Is Potentially 20% Below Its Share PriceJuly 1, 2022 | lse.co.ukSMALL-CAP WINNERS & LOSERS: Oxford BioMedica rises on AstraZeneca dealJuly 1, 2022 | seekingalpha.comAstraZeneca signs new three-year deal with Oxford Biomedica for COVID shotSee More Headlines Receive OXBDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:OXBDF Previous SymbolNASDAQ:OXBDF CUSIPN/A CIKN/A Webwww.oxfordbiomedica.co.uk Phone44-18-6578-3000FaxN/AEmployees891Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$173.19 million Price / Sales1.62 Cash FlowN/A Price / Cash FlowN/A Book Value$3.03 per share Price / Book0.96Miscellaneous Outstanding Shares96,260,000Free FloatN/AMarket Cap$280.12 million OptionableNot Optionable Beta1.15 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Stuart Paynter (Age 52)CFO & Director Comp: $1.05MDr. Frank Mathias (Age 62)CEO & Director Mr. Thierry CournezCOO & Site Head of UK OperationsDr. James Miskin Ph.D.Chief Quality & Technical OfficerMr. Matthew TreagusChief Information Officer & Chief of StaffSophia BolhassanHead of Investor RelationsMs. Natalie Louise Walter (Age 51)General Counsel & Company Secretary Ms. Lisa JamesChief People OfficerDr. Kyriacos Mitrophanous Ph.D.Chief Innovation OfficerMs. Kati HudsonHead of Intellectual Property and ContractsMore ExecutivesKey CompetitorsAdociaOTCMKTS:ADOCYAngioDynamicsNASDAQ:ANGOFennec PharmaceuticalsNASDAQ:FENCXeris BiopharmaNASDAQ:XERSXBiotechNASDAQ:XBITView All Competitors OXBDF Stock Analysis - Frequently Asked Questions Should I buy or sell Oxford Biomedica stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford Biomedica in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" OXBDF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OXBDF, but not buy additional shares or sell existing shares. View OXBDF analyst ratings or view top-rated stocks. How have OXBDF shares performed in 2024? Oxford Biomedica's stock was trading at $2.69 at the start of the year. Since then, OXBDF shares have increased by 8.2% and is now trading at $2.91. View the best growth stocks for 2024 here. Are investors shorting Oxford Biomedica? Oxford Biomedica saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 800 shares, a drop of 42.9% from the March 31st total of 1,400 shares. Based on an average daily trading volume, of 200 shares, the short-interest ratio is currently 4.0 days. View Oxford Biomedica's Short Interest. How do I buy shares of Oxford Biomedica? Shares of OXBDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:OXBDF) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsProtect Your Bank Account Before It’s Too LateWeiss RatingsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxford Biomedica plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
